6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease

This publication has 33 references indexed in Scilit:

• Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for "6-MP resistance"
  Gastroenterology, 2000
• Investigation of a potential drug interaction between azathioprine (AZA)/6-mercaptopurine (6MP) and sulfasalazine (SAS), mesalamine (Pentasa) or balsalazide among patients with Crohn's disease (CD)
  Gastroenterology, 2000
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• Toxicities and infections associated with chronic 6-Mercaptopurine (6-MP) use in Crohn's disease (CD): do we need to discontinue treatment?
  Gastroenterology, 1998
• 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
  Gut, 1996
• A controlled double blind study of azathioprine in the management of Crohn??s disease
  European Journal of Gastroenterology & Hepatology, 1995
• Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.
  BMJ, 1992
• Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
  The Lancet, 1990
• Peliosis hepatis induced by 6-thioguanine administration.
  Gut, 1988
• Treatment of Crohn's Disease with 6-Mercaptopurine
  New England Journal of Medicine, 1980